Meeting
2018 ASCO Annual Meeting
Impact of somatic mutations on recurrence free survival (RFS) and overall survival (OS) for resected non-small cell lung cancer (NSCLC): results from the Japan Molecular Epidemiology for lung cancer study (JME).
Authors
Akihiro Tamiya
National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Japan
Akihiro Tamiya , Yasuhiro Koh , Akihito Kubo , Masahiko Ando , Shun-ichi Isa , Hideo Saka , Naoki Yoshimoto , Masakuni Serizawa , Sadanori Takeo , Hirofumi Adachi , Tsutomu Tagawa , Osamu Kawashima , Motohiro Yamashita , Kazuhiko Kataoka , Yukito Ichinose , Yukiyasu Takeuchi , Katsuya Watanabe , Akihide Matsumura , Tomoya Kawaguchi
Organizations
National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Japan, Wakayama Medical University, Wakayama, Japan, Division of Respiratory Medicine and Allergology, Aichi Medical University School of Medicine, Nagakute, Japan, Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan, Department of Respiratory Medicine, Nagoya Medical Center, Nagoya, Japan, Department of Clinical Oncology, Osaka City University, Graduate School of Medicine, Osaka, Japan, Division of Drug Discovery and Development, Shizuoka Cancer Center Research Institute, Nagaizumi-Cho, Shizuoka, Japan, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan, Department of Thoracic Surgery, National Hospital Organization, Hokkaido Cancer Center, Hokkaido, Japan, National Hospital Organization Nagasaki Medical Center, Omura, Japan, National Hospital Organization Shibukawa Medical Center, Shibukawa, Japan, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan, National Hospital Organization Iwakuni Clinical Center, Iwakuni, Japan, National Hospital Organization Kyushu Cancer Center, Fukuoka-Shi, Japan, National Hospital Organization Toneyama National Hospital, Toyonaka, Japan, National Hospital Organization Yokohama Medical Center, Yokohama City, Japan, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan, Department of Respiratory Medicine, Osaka City University, Graduate School of Medicine, Osaka, Japan
Research Funding
Other Foundation
Background: We previously reported molecular profiling as a primary endpoint in a prospective multicenter molecular epidemiology study, collecting 876 surgically resected NSCLC and examining 72-gene somatic mutation status using the next-generation sequencing (JME study; Kawaguchi T, J Clin Oncol 2016). The secondary endpoint was OS and RFS analysis (UMIN 000008177). Here, we report follow-up data and clinical outcomes in the JME study and the impact of somatic mutations on RFS and OS. Methods: All the patients were enrolled from July 2012 to December 2013, and clinical and prognostic data were obtained until the end of November 2017. Cox proportional hazards model were applied to assess the impact of the gene mutations on RFS and OS, considering gender, smoking history, age, stage, histology, history of adjuvant chemotherapy, EGFR, KRAS, TP53, and number of coexisting mutations. Results: Median follow up time was 48.4 months, and 876 patients were analyzed: 419 were men; 734 were non-squamous carcinoma; 441 had smoking history; 450 were ≥70 years; 618/131/127 were stage I/II/III-IV, 309 received the adjuvant chemotherapy. Among these, 141 had ≥ two somatic mutations. Multivariate analysis showed the number of coexisting mutations (≥2 vs. 0 or 1, HR = 1.643, 95%CI: 1.126-2.373), age (≥70 vs. < 70, HR = 1.561, 95%CI: 1.201-2.035) and pathological stage (II vs. I, HR = 3.103, 95%CI: 2.217-4.304; ≥III vs. I, HR = 6.382, 95%CI: 4.641-8.758) were significantly associated with RFS, while in OS, EGFR mutations (yes vs. no, HR = 0.450, 95%CI: 0.277-0.715), adjuvant chemotherapy (yes vs. no, HR = 0.493, 95%CI: 1.406-2.967), age (≥70 vs. < 70, HR = 1.694, 95%CI: 1.201-2.415) and pathological stage (II vs. I, HR = 2.448, 95%CI: 1.581-3.723; ≥III vs. I, HR = 6.601, 95%CI: 4.498-9.665) were also significant prognostic factors. Conclusions: Our prospective study showed less number of coexisting mutations, earlier stage and younger age were associated with longer RFS, while in OS, EGFR mutation and adjuvant chemotherapy were significantly associated with improved OS as well as earlier stage and younger age in resected NSCLC.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Citation
J Clin Oncol 36, 2018 (suppl; abstr 8549)
DOI
10.1200/JCO.2018.36.15_suppl.8549
Abstract #
8549
Poster Bd #
155
Abstract Disclosures
Similar Abstracts
Abstract
2023 ASCO Annual Meeting
The RESECT study: Factors associated with overall survival (OS) and relapse-free survival (RFS) among patients with stages I–III resected NSCLC without known EGFR mutations.
First Author: Jhanelle Elaine Gray
Abstract
2023 ASCO Annual Meeting
Development and validation of a prediction model for the recurrence of stage 1 EGFR mutation positive NSCLC in patients using machine learning with WES-based gene sets.
First Author: Akiko Tateishi
Abstract
2023 ASCO Annual Meeting
ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent KRAS G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC).
First Author: Sukhmani Kaur Padda
Abstract
2024 ASCO Gastrointestinal Cancers Symposium
Association between TP53 gain of function and loss of function mutational subgroups and survival in pancreatic adenocarcinoma.
First Author: Nitzan Zohar